Ret inhibitor for use in treating cancer having a ret alteration
AssigneeBlueprint Medicines Corporation
InventorsErica Evans Raab, Beni B. Wolf
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.
Claims23
-64. (canceled)
A method of treating a subject with a rearranged during transfection (RET)—altered cancer, the method comprising administering to the subject once daily 100 mg to 400 mg of Compound 1 or a pharmaceutically acceptable salt thereof, wherein Compound 1 is:
A method of treating a subject with a rearranged during transfection (RET)—altered cancer, the method comprising orally administering to the subject once daily one or more solid dosage forms each comprising a pharmaceutically acceptable excipient and 100 mg of Compound 1, wherein Compound 1 is:
Dependencies are inferred from the claim text.